The World's First AI-Designed Vaccine Successfully Completes Human Trials

The vaccine targets the entire Sarbecovirus family and, in Phase 1 trials (39 volunteers), demonstrated good tolerability and a strong immune response — including neutralizing antibodies not only against the current coronavirus, but also against SARS-CoV-1 and several bat strains.

Particularly promising is the fact that this vaccine can be used in needle-free delivery systems (such as nasal sprays or skin patches), which would significantly simplify vaccination in the future.

"We have shown that AI is capable of creating broad-spectrum vaccines that could potentially protect against future pandemics," the authors noted.

This is only Phase 1 — a safety and immunogenicity check. Larger trials will be required to confirm efficacy. Nevertheless, the result is considered an important milestone on the path toward universal next-generation vaccines.

Sources: University of Cambridge. AI-designed universal coronavirus vaccine passes first human trial. Journal of Infection, 2026. Press release by the University of Cambridge and ScienceDaily (June 5, 2026).